ELOC: A Protein in Various Physiological Processes and Potential Drug Target Or Biomarker for Cancer

Target Name: ELOC

NCBI ID: G6921

ELOC

ELOC: A Protein in Various Physiological Processes and Potential Drug Target Or Biomarker for Cancer

ELOC (Elongin C, transcript variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the elongin family of proteins, which are known for their role in intracellular signaling and cell-cell adhesion.

ELOC has been shown to play a role in a variety of physiological processes in the body, including cell signaling, migration, and invasion. It has also been shown to be involved in the development and progression of a number of diseases, including cancer.

Recent studies have suggested that ELOC may be a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential mechanism by which ELOC may be involved in the development and progression of cancer is its role in cell signaling. ELOC has been shown to play a negative role in the regulation of cell proliferation and survival, and it has been shown to interact with a variety of signaling pathways, including the TGF-β pathway. This suggests that ELOC may be involved in the regulation of cell growth and differentiation, and that its dysfunction in these processes could be a potential target for cancer therapies.

Another potential mechanism by which ELOC may be involved in the development and progression of cancer is its role in cell migration and invasion. ELOC has been shown to play a role in the regulation of cell adhesion and migration, and it has been shown to interact with a variety of signaling pathways, including the PDGF pathway. This suggests that ELOC may be involved in the regulation of cell movement and that its dysfunction in these processes could be a potential target for cancer therapies.

In addition to its potential role in cancer development, ELOC has also been shown to be involved in the regulation of a variety of other physiological processes in the body. For example, it has been shown to play a role in the regulation of cell signaling and protein synthesis, and it has been shown to interact with a variety of signaling pathways, including the NF-kappa-B pathway.

Given the potential involvement of ELOC in a variety of physiological processes in the body, it is a promising target for drug development and research. Further studies are needed to fully understand the function of ELOC and its potential as a drug target or biomarker.

Protein Name: Elongin C

Functions: SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex) (PubMed:7821821). In embryonic stem cells, the elongin BC complex is recruited by EPOP to Polycomb group (PcG) target genes in order generate genomic region that display both active and repressive chromatin properties, an important feature of pluripotent stem cells (By similarity)

The "ELOC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets